The company is making a shift to focus on only the highest-value GenAI use cases and shut down pilots that were redundant or ...

Johnson & Johnson is increasing its dividend for the 63rd consecutive year. This further cements the healthcare giant's ...

For medical-technology and pharmaceuticals manufacturing, “the most effective answer is not tariffs but tax policy,” Johnson ...

Health care giant Johnson & Johnson expects about $400 million in tariff-related costs this year. The costs will be felt ...

Morgan Stanley raised the firm’s price target on Johnson & Johnson to $169 from $164 and keeps an Equal Weight rating on the shares after ...

Raymond James raised the firm’s price target on Johnson & Johnson to $164 from $162 and keeps an Outperform rating on the shares. The firm ...

Health care giant Johnson & Johnson expects about $400 million in tariff-related costs this year. The costs will be felt primarily within the company's medical technology unit, which makes a range of ...

Johnson & Johnson Chief Executive Joaquin Duato said on Tuesday that tariffs on pharmaceuticals can create supply chain ...